Dr Lal PathLabs to acquire Delta Ria and Pathology

Diagnostic chain Dr Lal PathLabs today said it will fully acquire Delta Ria and Pathology while increasing its stake in group firms Paliwal Diagnostics and Paliwal Medicare by 10 per cent each.
Without sharing the total value of the acquisition, the company said it will fully acquire Delta Ria and Pathology for a price of not more than Rs 8,272.51 per share.
Similarly, the additional stake in Paliwal Diagnostics will be acquired at a price of not more than Rs 65,343 per share for and Rs 39,439 per share for Paliwal Medicare. Post the acquisition, the company's stake in the two entities will go up to 80 per cent from 70 per cent previously, Dr Lal PathLabs said in a BSE filing.

The company said its board at its meeting held today has "approved acquisition of Delta Ria and Pathology Pvt Ltd and acquisition of additional 10 per cent stake in Paliwal Diagnostics Pvt Ltd and Paliwal Medicare Pvt Ltd."
While the acquisition of Delta Ria and Pathology is not a related party transaction, acquisition of 10 per cent stake in the two firms is related party transaction as both firms are subsidiaries of the company, it added.